Progress of targeted therapy in relapsed/refractory acute myeloid leukemia

VernacularTitle:复发难治急性髓系白血病靶向治疗研究进展
Author: Mengli TIAN ¹ ; Huiying QIU
Author Information

1. 国家血液系统疾病临床医学研究中心　江苏省血液研究所　苏州大学附属第一医院血液科，江苏　苏州　215006
Keywords: Leukemia, myeloid, acute; Relapsed; Refractory; Molecular targeted therapy
From: Journal of Leukemia & Lymphoma 2021;30(9):513-517
CountryChina
Language:Chinese
Abstract: At present, the treatment of relapsed/refractory acute myeloid leukemia (AML) is still challenging, and there is no standard treatment for relapsed/refractory AML patients. Current research believes that participating in clinical trials involving small molecule targeted therapy, immunotherapy and epigenetic therapy may be the best choice, but the efficacy and toxicity of clinical trials have not been widely evaluated, and the long-term survival of patients is not clear, so the prognosis of relapsed/refractory AML is still very poor. The future direction of research will focus on novel, effective and targeted treatment combinations, and low toxicity, personalized and accurate treatment strategies. This article reviews the latest progress in targeted therapy for relapsed/refractory AML.